Alliance Pharma PLC Notice of Results (9431X)
August 16 2018 - 1:01AM
UK Regulatory
TIDMAPH
RNS Number : 9431X
Alliance Pharma PLC
16 August 2018
For immediate release 16 August 2018
ALLIANCE PHARMA PLC
("Alliance" or the "Company")
Notification of Interim Results
Alliance Pharma plc (AIM: APH), the international specialty
pharmaceutical company, will announce its interim results for the
six months ended 30 June 2018 on Wednesday 19 September 2018.
A briefing for analysts will be held at 10.00am on the morning
of the results at the offices of Buchanan, 107 Cheapside, London
EC2V 6DN.
For more information, or to register attendance, please contact
Buchanan on 020 7466 5000.
For further information:
Alliance Pharma plc + 44 (0) 1249 466966
Peter Butterfield, Chief Executive Officer
Andrew Franklin, Chief Financial Officer
www.alliancepharma.co.uk
Buchanan + 44 (0) 20 7466 5000
Mark Court / Sophie Wills / Gemma Mostyn-Owen
Numis Securities Limited + 44 (0) 20 7260 1000
Nominated Adviser: Michael Meade / Freddie Barnfield
Corporate Broking: James Black / Toby Adcock
Investec Bank plc +44 (0) 20 7597 5970
Corporate Finance: Daniel Adams / Ed Thomas
Corporate Broking: Patrick Robb / David Herring
Notes to editors:
Alliance Pharma plc is an international specialty pharmaceutical
company.
Headquartered in Chippenham, UK, Alliance commenced trading in
1998 and has been listed on AIM since 2003. Alliance has a strong
track record of acquiring established niche products and it
currently owns or licenses the rights to approximately 90
pharmaceutical and consumer healthcare products. It has sales in
more than 100 countries either directly via its affiliates or
through its selected network of distributor partners. Alliance
joined the AIM market of the London Stock Exchange in December 2003
and trades under the symbol APH.
For more information on Alliance, please visit our website:
www.alliancepharmaceuticals.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NORMMGMRVKKGRZM
(END) Dow Jones Newswires
August 16, 2018 02:01 ET (06:01 GMT)
Alliance Pharma (LSE:APH)
Historical Stock Chart
From Apr 2024 to May 2024
Alliance Pharma (LSE:APH)
Historical Stock Chart
From May 2023 to May 2024